The popularity of Viagra initially fueled a boom for major pharmaceutical companies, nevertheless recent changes present a murky scenario for investors. Lower-cost competitors are eroding profits, and persistent litigation add additional complexity to the situation. While specific companies may still benefit from related products, the general trend